跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 7,874 条关于
“AB2 BIO”
全部
7,874
临床试验
3,907
药物
1,502
机构
515
资讯
1,950
去年
AB2 Bio and Nippon Shinyaku Strike $686M Deal for Rare Disease Drug Tadekinig Alfa
上个月
Nippon Shinyaku Exercises Option for AB2 Bio's Tadekinig Alfa, Securing U.S. Commercialization Rights for Rare Autoinflammatory Diseases
上个月
Nippon Shinyaku Exercises $30 Million U.S. Commercialization Option for AB2 Bio's Tadekinig Alfa in Ultra-Rare Pediatric Hyperinflammatory Syndrome
9个月前
ABL Bio and NEOK Bio Advance First-in-Class Bispecific ADC ABL206 to Phase 1 Clinical Trial
去年
STGen Bio's Songdo Plant Secures FDA cGMP Approval, Expanding Global Reach
去年
GSK Expands Neurodegenerative Disease Portfolio with $2.5B+ ABL Bio Partnership
去年
ABL Bio Secures Major Platform Deal with GSK, Eyes Future Acquisition
去年
Tolerance Bio Partners with ZipCode Bio to Develop Targeted Thymus Therapeutics for Immune Aging
去年
ABL Bio Terminates ADC Platform Technology Contract with Intussell Over Patent Concerns
去年
ABL Bio Receives Regulatory Approval for Triple Combination Cancer Therapy Trial
第 1 页,共 195 页
上一页
下一页